Eli Lilly is making its osteoporosis drug, Foundayo, available privately in the UK and is seeking a NICE assessment for NHS use at a proposed price of £100-£120. This move expands market access for the drug while initiating the process for broader public healthcare coverage.
Eli Lilly is strategically expanding the market for its osteoporosis drug, Foundayo, by first making it available privately in the UK. Concurrently, the company is pursuing a NICE assessment for NHS inclusion, proposing a price range of £100-£120. This dual approach allows for immediate revenue generation from private sales while working towards broader, long-term market penetration through the NHS. For Eli Lilly, this represents a positive step in commercializing Foundayo, potentially increasing its revenue stream in the UK. The short-term implication is a modest revenue boost from private sales, with a larger, more significant opportunity if NICE approves NHS use, which would greatly expand patient access and sales volume. The key opportunity for traders is the potential for increased sales and market share for LLY if the NHS approval is granted.